JNJ · News · 20260917N
Guidance and Outlook
JOHNSON & JOHNSON · 2026-09-17 · Importance 46 · Surprise 42 · In source text
CFO Joe Wolk said Johnson & Johnson sees a path to growth above its previously stated 5% to 7% long-term range. He attributed the potential acceleration to the pharmaceutical pipeline, the medical technology portfolio, and capital flexibility. The outlook is being considered despite a 2026 patent cliff, which may pressure products losing exclusivity.
Key facts
- Johnson & Johnson Executive Vice President and Chief Financial Officer Joe Wolk said the company sees a path to growth above its previously stated 5% to 7% long-term range. source
- Johnson & Johnson faces billions in talc-related litigation liabilities (as stated in the article). source
- Johnson & Johnson has raised its dividend for 64 straight years. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Johnson & Johnson Executive Vice President and Chief Financial Officer Joe Wolk said the company sees a path to growth above its… |
| liability | negative | contingent | — | Johnson & Johnson faces billions in talc-related litigation liabilities (as stated in the article). |